I

InflaRx NV

D
IFRX
USD
0
(0%)
Market Closed
7,088.00
Volume
-0.98785
EPS
-
Div Yield
-1.770726
P/E
90,091,406.16
Market Cap
Today
-4.0752%
1 Week
-1.290%
1 Month
1.325%
6 Months
24.390%
12 Months
4.082%
Year To Date
-6.135%
All Time
0%

Title:
InflaRx NV

Sector:
Healthcare
Industry:
Biotechnology
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Do you need help or have a question?